Search for BIO Diagnostic and Prognostic Markers in Adult VAScularitis

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

225 participants

Study Classification

OBSERVATIONAL

Study Start Date

2022-11-22

Study Completion Date

2037-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

To date, there are no reliable diagnostic blood markers of adult vasculitis. To date, the diagnosis of vasculitis is based on invasive procedure, biopsy of affected tissues potentially at risk of complication . In addition, there are no reliable biomarkers to predict the evolution of vasculitis (relapse, refractory form ...) necessary for the management of patients (type of treatment, duration ..)

Prospective study, monocentric (CHU de Tours), non-interventional, aimed at finding diagnostic and prognostic biomarkers (both metabolomic and immunologic) in adult vasculitis patients.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Studies of the Natural History, Pathogenesis, and Outcome of Idiopathic Systemic Vasculitis

NCT02257866

Takayasu's Arteritis Giant Cell Arteritis Polyarteritis Nodosa +2 more

RECRUITING

Prognostic Value of Anti-Ro52 Antibodies in Connective Tissue Diseases (a-Ro52)

NCT03565601

Connective Tissue Diseases

UNKNOWN

Study of Lymphopenia as a Specific Biomarker or Prognostic Risk Factor for Disease Severity in Elderly Patients With COVID-19

NCT04800731

Lymphopenia Covid19 Older People

COMPLETED

Flemish Joint Effort for Biomarker PRofiling in Inflammatory Systemic Diseases

NCT05670301

Autoinflammatory Disease Autoimmune Diseases Inflammation

RECRUITING NA

Soluble CD95 Ligand Role in the Pathophysiology of Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis

NCT03698071

ANCA Associated Vasculitis

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Specimen will be collected at diagnosis, month 1, month 3, and month12 and at the time of a possible relapse. 14 ml of additional blood during a blood puncture made for routine care will be collected at each visit as well as clinical data.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Vasculitis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_ONLY

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

patients with vascularitis

Two additional 7ml EDTA tubes of blood are taken from the same blood puncture as during routine follow-up at several points in the follow-up

Sampling

Intervention Type OTHER

4 blood sampling per patient and an additional one in case of relapse

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Sampling

4 blood sampling per patient and an additional one in case of relapse

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age \> 16 years
* Active vasculitis, new diagnosis or relapse
* IgA vasculitis
* ANCA vasculitis
* Giant cell arteritis

Exclusion Criteria

* Person who has objected to the processing of data
* Pregnant woman
* Patient positive for HIV, HBV, HCV
* Treatment in the previous month with corticosteroids, immunosuppressive drugs or biotherapy.
* Patient unable to understand the information leaflet
* Adult under guardianship or curatorship

Minimum Eligible Age

16 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No